Zegbeh Jallah
Stock Analyst at Capital One
(4.63)
# 223
Out of 4,412 analysts
26
Total ratings
32%
Success rate
102.39%
Average return
Main Sectors:
Top Industries:
17 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OTLK Outlook Therapeutics | Upgrades: Overweight | $100 | $8.43 | +1,086.24% | 2 | Dec 27, 2023 | |
| GLYC GlycoMimetics | Initiates: Overweight | $12 | $1.64 | +631.71% | 1 | Dec 22, 2023 | |
| EYPT EyePoint Pharmaceuticals | Initiates: Overweight | $44 | $16.75 | +162.69% | 1 | Dec 11, 2023 | |
| KOD Kodiak Sciences | Upgrades: Overweight | n/a | $3.28 | - | 4 | Nov 17, 2023 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $29 | $39.94 | -27.39% | 2 | Dec 28, 2022 | |
| RAPT RAPT Therapeutics | Initiates: Overweight | $48 | $8.10 | +492.59% | 2 | Sep 21, 2022 | |
| ENTA Enanta Pharmaceuticals | Maintains: Buy | $101 → $70 | $12.37 | +465.89% | 2 | May 12, 2022 | |
| SYRS Syros Pharmaceuticals | Maintains: Buy | n/a | $5.04 | - | 1 | Sep 23, 2021 | |
| LIFE aTyr Pharma | Maintains: Buy | n/a | $1.57 | - | 2 | Sep 14, 2021 | |
| RZLT Rezolute | Initiates: Buy | n/a | $2.66 | - | 1 | Sep 8, 2021 | |
| ARVN Arvinas | Maintains: Buy | n/a | $32.37 | - | 1 | Aug 9, 2021 | |
| DARE Daré Bioscience | Maintains: Buy | n/a | $0.31 | - | 1 | Jun 30, 2021 | |
| OCGN Ocugen | Downgrades: Neutral | n/a | $1.28 | - | 2 | Jun 11, 2021 | |
| KALV KalVista Pharmaceuticals | Maintains: Buy | n/a | $10.78 | - | 1 | Feb 18, 2021 | |
| IVA Inventiva | Initiates: Buy | n/a | $3.25 | - | 1 | Aug 5, 2020 | |
| CLSD Clearside Biomedical | Initiates: Buy | n/a | $1.34 | - | 1 | May 13, 2020 | |
| XFOR X4 Pharmaceuticals | Initiates: Buy | n/a | $1.17 | - | 1 | Dec 18, 2019 |
Outlook Therapeutics
Dec 27, 2023
Upgrades: Overweight
Price Target: $100
Current: $8.43
Upside: +1,086.24%
GlycoMimetics
Dec 22, 2023
Initiates: Overweight
Price Target: $12
Current: $1.64
Upside: +631.71%
EyePoint Pharmaceuticals
Dec 11, 2023
Initiates: Overweight
Price Target: $44
Current: $16.75
Upside: +162.69%
Kodiak Sciences
Nov 17, 2023
Upgrades: Overweight
Price Target: n/a
Current: $3.28
Upside: -
IDEAYA Biosciences
Dec 28, 2022
Initiates: Overweight
Price Target: $29
Current: $39.94
Upside: -27.39%
RAPT Therapeutics
Sep 21, 2022
Initiates: Overweight
Price Target: $48
Current: $8.10
Upside: +492.59%
Enanta Pharmaceuticals
May 12, 2022
Maintains: Buy
Price Target: $101 → $70
Current: $12.37
Upside: +465.89%
Syros Pharmaceuticals
Sep 23, 2021
Maintains: Buy
Price Target: n/a
Current: $5.04
Upside: -
aTyr Pharma
Sep 14, 2021
Maintains: Buy
Price Target: n/a
Current: $1.57
Upside: -
Rezolute
Sep 8, 2021
Initiates: Buy
Price Target: n/a
Current: $2.66
Upside: -
Arvinas
Aug 9, 2021
Maintains: Buy
Price Target: n/a
Current: $32.37
Upside: -
Daré Bioscience
Jun 30, 2021
Maintains: Buy
Price Target: n/a
Current: $0.31
Upside: -
Ocugen
Jun 11, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.28
Upside: -
KalVista Pharmaceuticals
Feb 18, 2021
Maintains: Buy
Price Target: n/a
Current: $10.78
Upside: -
Inventiva
Aug 5, 2020
Initiates: Buy
Price Target: n/a
Current: $3.25
Upside: -
Clearside Biomedical
May 13, 2020
Initiates: Buy
Price Target: n/a
Current: $1.34
Upside: -
X4 Pharmaceuticals
Dec 18, 2019
Initiates: Buy
Price Target: n/a
Current: $1.17
Upside: -